Medtronic (MDT) Stock Forecast & Price Target

$102.84 +1.85 (+1.83%)

Closing price 11/13/2026 03:59 PM Eastern

Extended Trading

$103.00 +0.16 (+0.16%)

As of 11/13/2026 08:00 PM Eastern

Compare

Medtronic - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 28 Analyst Ratings

Sell
1

Hold
9

Buy
18

Based on 28 Wall Street analysts who have issued ratings for Medtronic in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 28 analysts, 1 has given a sell rating, 9 have given a hold rating, and 18 have given a buy rating for MDT.

Consensus Price Target

$102.88
0.04% Upside

According to the 28 analysts' twelve-month price targets for Medtronic, the average price target is $102.88. The highest price target for MDT is $118.00, while the lowest price target for MDT is $83.00. The average price target represents a forecasted upside of 0.04% from the current price of $102.84.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for MDT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Medtronic and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MDT Analyst Ratings Over Time

Type	Current Forecast 11/14/25 to 11/14/26	1 Month Ago 10/15/25 to 10/15/26	3 Months Ago 8/16/25 to 8/16/26	1 Year Ago 11/14/24 to 11/14/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	18 Buy rating(s)	17 Buy rating(s)	18 Buy rating(s)	11 Buy rating(s)
Hold	9 Hold rating(s)	10 Hold rating(s)	9 Hold rating(s)	9 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$102.88	$102.88	$98.83	$103.06
Forecasted Upside	0.04% Upside	7.29% Upside	8.48% Upside	7.44% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

MDT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MDT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Medtronic Stock vs. The Competition

Type	Medtronic	Healthcare Companies	Broader Market
Consensus Rating Score	2.61	2.32	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	0.04% Upside	115.11% Upside	14.68% Upside
News Sentiment Rating	Positive News See Recent MDT News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/19/2026	Weiss Ratings 2 of 5 stars		Upgrade	Hold (C+) ➝ Buy (B-)
10/14/2026	Piper Sandler 2 of 5 stars	Matt O'Brien 2 of 5 stars	Reiterated Rating	Neutral
10/14/2026	UBS Group 4 of 5 stars	Priya Sachdeva Not Rated	Reiterated Rating	Cautious
10/12/2026	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Ryan Zimmerman Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Buy	$100.00 ➝ $99.00	+11.79%
10/7/2026	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Christopher Pasquale Subscribe to MarketBeat All Access to unlock analyst rankings	Upgrade	Hold
9/30/2026	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Joshua Jennings Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Buy	$110.00	+26.20%
9/17/2026	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Mike Matson Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Buy
9/3/2026	Deutsche Bank Subscribe to MarketBeat All Access to unlock brokerage rankings		Reiterated Rating	Hold	$92.00	-0.04%
9/2/2026	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Anthony Petrone Subscribe to MarketBeat All Access to unlock analyst rankings	Set Target		$115.00	+24.86%
9/2/2026	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Bob Hopkins Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Buy	$95.00 ➝ $110.00	+19.67%
Get the Latest News and Ratings for MDT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Medtronic and its competitors with MarketBeat's FREE daily newsletter.
9/2/2026	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Lawrence Biegelsen Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Overweight	$102.00 ➝ $104.00	+13.14%
9/2/2026	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Richard Newitter Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Hold	$86.00 ➝ $99.00	+7.70%
9/2/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Kendall Au Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Outperform	$118.00	+28.37%
9/2/2026	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	David Rescott Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Neutral	$91.00 ➝ $100.00	+8.79%
9/2/2026	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Rick Wise Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Hold	$80.00 ➝ $95.00	+3.35%
7/6/2026	Evercore Subscribe to MarketBeat All Access to unlock brokerage rankings	Vijay Kumar Subscribe to MarketBeat All Access to unlock analyst rankings	Set Target		$105.00	+27.49%
6/5/2026	Rothschild & Co Redburn Subscribe to MarketBeat All Access to unlock brokerage rankings		Lower Target	Buy	$111.00 ➝ $106.00	+28.58%
6/4/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access to unlock brokerage rankings	Lee Hambright Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Outperform	$112.00 ➝ $97.00	+17.46%
6/4/2026	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Matthew Taylor Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Hold	$88.00	+12.70%
6/4/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings		Lower Target	Neutral	$100.00 ➝ $86.00	+4.07%
6/4/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access to unlock brokerage rankings	David Roman Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Neutral	$84.00 ➝ $83.00	+0.55%
6/4/2026	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Mike Kratky Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Outperform	$117.00 ➝ $104.00	+33.19%
4/7/2026	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Joanne Wuensch Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Buy	$117.00 ➝ $110.00	+27.75%
4/6/2026	Argus Subscribe to MarketBeat All Access to unlock brokerage rankings	David Toung Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Buy	$125.00 ➝ $115.00	+32.76%
2/27/2026	Daiwa Securities Group Subscribe to MarketBeat All Access to unlock brokerage rankings		Lower Target	Buy	$117.00 ➝ $115.00	+17.83%
1/30/2026	CICC Research Subscribe to MarketBeat All Access to unlock brokerage rankings		Initiated Coverage	Outperform
1/6/2026	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Brandon Vazquez Subscribe to MarketBeat All Access to unlock analyst rankings	Upgrade	Market Perform ➝ Outperform
11/19/2025	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Cecilia Furlong Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Overweight	$107.00 ➝ $117.00	+16.20%
6/30/2025	Wolfe Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Mike Polark Subscribe to MarketBeat All Access to unlock analyst rankings	Upgrade	Underperform ➝ Peer Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 11:33 AM ET.

Should I Buy Medtronic Stock? MDT Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, November 12, 2026. Please send any questions or comments about these Medtronic pros and cons to contact@marketbeat.com.

Medtronic
Bull Case

Here are some ways that investors could benefit from investing in Medtronic plc:

Medtronic plc shares are currently trading at $100.96, which is below the average analyst price target of $102.88, suggesting potential for near-term upside as the stock consolidates after a strong recovery from its 52-week low of $73.31.
The company demonstrated strong fundamental performance in its most recent quarter, reporting earnings per share of $1.45, which exceeded the consensus estimate of $1.39, alongside revenue of $9.76 billion that beat expectations and grew 13.7% year-over-year.
Short interest in Medtronic plc dropped significantly by 83.5% in October, falling to 22,952,253 shares, which indicates that a large portion of bearish bets have been closed out, potentially reducing downward pressure on the stock price.
Medtronic plc offers a dividend yield of 2.80%, providing a steady income stream for investors, supported by a payout ratio of 70.94% that remains manageable given the company's net margin of 13.93%.
The stock has a low beta of 0.56, meaning it is less volatile than the broader market, which can make it a stabilizing addition to a diversified portfolio during periods of market uncertainty.

Medtronic
Bear Case

Investors should be bearish about investing in Medtronic plc for these reasons:

Medtronic plc initiated two Class II device recalls in November 2026 for the OmniaSecure Model 3930M cardiac lead and the CareLink SmartSync Programmer, which could lead to increased costs, regulatory scrutiny, and potential reputational damage.
Corporate insiders have been selling shares recently, with CEO Geoffrey Martha selling 50,000 shares and EVP Michael Marinaro selling 10,420 shares in October 2026, which may signal a lack of confidence in the stock's near-term performance.
Several large institutional investors, including M&G PLC and Beutel Goodman & Co Ltd., reduced their positions in Medtronic plc during the third quarter, with M&G PLC selling 185,546 shares and Beutel Goodman trimming its stake by 6.6%.
The company's price-to-earnings ratio stands at 24.87, which is relatively high compared to its historical averages, suggesting that the stock may be overvalued relative to its current earnings power.
Medtronic plc faces competition from other healthcare giants, and recent news highlights comparisons with Abbott, which may pressure Medtronic's market share and pricing power in key therapeutic areas.

MDT Forecast - Frequently Asked Questions

According to the research reports of 28 Wall Street equities research analysts, the average twelve-month stock price forecast for Medtronic is $102.88, with a high forecast of $118.00 and a low forecast of $83.00.

28 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medtronic in the last year. There is currently 1 sell rating, 9 hold ratings and 18 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MDT shares.

According to analysts, Medtronic's stock has a predicted upside of 0.04% based on their 12-month stock forecasts.

Over the previous 90 days, Medtronic's stock had 3 upgrades by analysts.

Medtronic has been rated by research analysts at Bank of America, Barclays, BTIG Research, Deutsche Bank, Mizuho, Needham & Company LLC, Piper Sandler, Robert W. Baird, Royal Bank Of Canada, Stifel Nicolaus, TD Cowen, Truist Financial, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Medtronic more than other "healthcare" companies. The consensus rating for Medtronic is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how MDT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Medtronic Recommendations

MarketBeat monitors more than a dozen sources for Medtronic analyst ratings, with the most recent rating issued on 10/19/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medtronic (MDT) Stock Forecast & Price Target